Germany · Delayed Price · Currency is EUR Ironwood Pharmaceuticals Company Description
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.
It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease.
It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.
The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008.
Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 1998 |
| Industry | Pharmaceutical Preparations |
| Employees | 253 |
| CEO | Thomas McCourt |
Contact Details
Address: 100 Summer Street Boston, Delaware 02110 United States | |
| Phone | 617 621 7722 |
| Website | ironwoodpharma.com |
Stock Details
| Ticker Symbol | I76 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas McCourt | Chief Executive Officer |
| Gregory Martini | Chief Financial Officer |
| Gregory Martini | Head of Investor Relations |